Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2005

01-06-2005

The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li–Fraumeni-like kindreds

Authors: Rina Siddiqui, Kenan Onel, Flavia Facio, Kedoudja Nafa, Louis Robles Diaz, Noah Kauff, Helen Huang, Mark Robson, Nathan Ellis, Kenneth Offit

Published in: Familial Cancer | Issue 2/2005

Login to get access
Metadata
Title
The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li–Fraumeni-like kindreds
Authors
Rina Siddiqui
Kenan Onel
Flavia Facio
Kedoudja Nafa
Louis Robles Diaz
Noah Kauff
Helen Huang
Mark Robson
Nathan Ellis
Kenneth Offit
Publication date
01-06-2005
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 2/2005
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-004-1946-5

Other articles of this Issue 2/2005

Familial Cancer 2/2005 Go to the issue

Letter to the editor

The BRCA1 exon 13 duplication in the Swedish population

OriginalPaper

Abdominal desmoid in familial adenomatous polyposis presenting as a pancreatic cystic lesion

OriginalPaper

Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients

OriginalPaper

Ratio of male to female births in the offspring of BRCA1 and BRCA2 carriers

OriginalPaper

The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews

OriginalPaper

Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits